ArticleNPJ cardiovascular health2026
Persistent and de novo postpartum hypertension: a scoping review of pathophysiology, evaluation, and management.
Article in NPJ cardiovascular health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum hypertension is high blood pressure following delivery that may occur as persistent or de novo postpartum hypertension. This scoping review summarizes current evidence on the epidemiology, risk factors, evaluation, and management of postpartum hypertension and highlights areas for further investigation. Studies on persistent or de novo hypertension in the 12-month postpartum period were eligible for inclusion. Literature searches were performed in MEDLINE, Embase, and Scopus. Of 2132 studies screened, 116 met the inclusion criteria. Postpartum hypertension epidemiologic data are limited, in part due to the absence of a standardized definition. Distinct risk factors for persistent versus de novo disease suggest differing underlying pathophysiologic mechanisms, yet trials of postpartum antihypertensive therapies have not identified a clear first-line agent. While telemedicine interventions have demonstrated improvements in postpartum hypertension outcomes, standardization of diagnostic and treatment thresholds and expanded research into mechanisms and therapeutics for persistent and de novo disease are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.